GlassScriptPhysician profile
Harrison G Sims
NPI 1568413219
$6,772.20
in general payments reported to CMS, 2019-2025
48 companies · $1,385 in 2025
The $1,385 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $746 · 2020: $674 · 2021: $592 · 2022: $781 · 2023: $1,336 · 2024: $1,258 · 2025: $1,385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,952 · Entertainment: $27.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,951.81 |
| Entertainment | $27.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,621.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $658.06 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $482.78 | 2019-2025 | Farxiga, Airsupra, Andexxa |
| Bayer Healthcare Pharmaceuticals INC. | $476.94 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $379.96 | 2019-2024 | Spravato, Xarelto |
| Pfizer INC. | $357.03 | 2019-2025 | |
| Lilly USA, LLC | $254.24 | 2020-2024 | Mounjaro, Jardiance, Emgality |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $237.01 | 2019-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $202.56 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $202.46 | 2024-2025 | Caplyta |
| Amgen INC. | $166.15 | 2019-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $151.04 | 2023 | Nucala, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $146.15 | 2019-2023 | |
| Lundbeck LLC | $133.29 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $100.21 | 2024-2025 | Auvelity, Sunosi |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $99.94 | 2019-2023 | Xyosted, Tlando, Nocdurna |
| Otsuka America Pharmaceutical, INC. | $92.13 | 2023-2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $87.94 | 2022-2025 | Gvoke Hypopen |
| Esperion Therapeutics, INC. | $70.80 | 2021-2024 | Nexletol |
| Eisai INC. | $66.30 | 2021 | |
| Novartis Pharmaceuticals Corporation | $57.85 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.79 | 2019-2021 | |
| Exact Sciences Corporation | $53.38 | 2024-2025 | Cologuard Collection Kit |
| Medtronic, INC. | $52.21 | 2023-2025 | Kyphon Express II Kyphopak Tray, Intellis Adaptivestim |
| Amarin Pharma, INC. | $51.54 | 2020-2021 | |
| Allergan, INC. | $39.81 | 2020 | |
| Merck Sharp & Dohme LLC | $39.59 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $35.42 | 2022-2023 | Nuzyra |
| Astellas Pharma US INC | $32.92 | 2023 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $32.08 | 2022-2024 | Eliquis |
| Optos, INC. | $27.51 | 2024-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Phathom Pharmaceuticals, INC. | $26.38 | 2024-2025 | Voquezna |
| Jazz Pharmaceuticals INC. | $24.48 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.44 | 2022 | |
| Corcept Therapeutics | $22.87 | 2025 | Korlym |
| Boston Scientific Corporation | $21.64 | 2023 | Wavewriter Alpha Prime 16 |
| Sumitomo Pharma America, INC. | $19.94 | 2025 | Gemtesa |
| Insulet Corporation | $18.76 | 2023 | Omnipod |
| Halozyme INC | $18.49 | 2023 | |
| Daiichi Sankyo INC. | $17.79 | 2022 | |
| Ironwood Pharmaceuticals, INC | $16.72 | 2020 | |
| Shield Therapeutics INC | $16.13 | 2025 | |
| Dexcom, INC. | $14.89 | 2023 | Dexcom G6 Transmitter |
| Medtronic Minimed, INC. | $14.35 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.66 | 2025 | Zoryve |
| Evoke Pharma, INC. | $13.11 | 2022 | |
| Clarus Therapeutics INC. | $12.02 | 2021 | |
| Sanofi Pasteur INC. | $11.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harrison Sims listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.